Approval Of Novel Drugs Is Expected To Boost Growth Of Gaucher Disease Treatment

Posted by Pareesh on June 6th, 2018

U.S. Food and Drug Administration (FDA) has approved multiple drugs in last few years for the treatment of disease. In 2010, FDA approved Vpriv (velaglucerase alfa), an enzyme replacement therapy (ERT), for type 1 Gaucher disease. In 2012, Elelyso (taliglucerase alfa) and in 2014, Cerdelga (eliglustat) was approved by FDA for type 1 Gaucher disease. These drugs offer variety of options based on their requirements, in turn is expected to boost the growth of the market.

In July 2017, The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) collaborated to promote the use of innovative approaches in the development of medicines for Gaucher disease. Such strategic collaboration of regulatory bodies for the development of novel innovative drugs is expected to boost the growth of Gaucher disease treatment market in near future. Lack of awareness regarding the symptoms, diagnosis, and treatment of disease among rural population is a major factor restraining market growth.

Request A Sample Copy Including Research Framework:

https://www.coherentmarketinsights.com/insight/request-sample/1225

North America is expected to hold the dominant position in the Gaucher disease treatment market due to increasing research activities for the development of novel drugs. In 2016, the scientist from National Institutes of Health researchers collaborated with National Institute of Neurological Disorders and Stroke (NINDS) and the National Center for Advancing Translational Sciences (NCATS). Researchers identified a new molecule that shows promising approach for treatment of the rare Gaucher disease. Europe is expected to be the second largest market for Gaucher disease treatment due to the initiative taken by European organizations to spread awareness about Gaucher disease among the population. For instance in 2014, European Gaucher Alliance launched Gaucher Awareness Day aiming to spread awareness about this rare disease among the European population.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702


Like it? Share it!


Pareesh

About the Author

Pareesh
Joined: May 31st, 2017
Articles Posted: 1,431

More by this author